! I’m your host today, Jessica Hergert.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Takeda, we had the pleasure of speaking with Elias Jabbour, MD, a professor in the Department of Leukemia and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, to discuss the use of TKIs in the treatment of patients with chronic myeloid leukemia (CML) and Philadelphia (Ph) chromosome–positive acute lymphoblastic leukemia (ALL).

In our exclusive interview, Jabbour discussed the optimal use of ponatinib in CML, recommendations for the treatment of patients with chronic phase–CML who progress after second-generations TKIs, and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab (Blincyto) and ponatinib (Iclusig) in Ph-positive ALL.

Podcasts

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Oncology Expert Insights

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia. 

Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL